GENESIS: Potency-Graded Contrastive Learning for Generative Molecular Design and Drug Repurposing in Oral Squamous Cell Carcinoma
Computational drug discovery typically binarizes bioactivity, discarding the graded doseresponse signal needed for lead prioritization. We introduce Potency-Graded Contrastive Learning (PGCL), projecting frozen molecular language-model embeddings into a 128dimensional space via an ordinal contrastive objective, six-tier negative taxonomy, and tier-margin ranking. Across three seeds, PGCL achieves Spearman ρ = 0.555 ± 0.003 for potency ordering and target-switch AUROC = 0.967, outperforming flat-contrastive and binaryclassification ablations and roughly doubling ECFP4 activity-cliff discrimination. Among six generative architectures, our reinforcement-learning method CRAVE (Contrastive Reward-Aligned VAE Exploration) significantly exceeds non-RL baselines on OSCC potency after Bonferroni correction (p = 0.016). The frozen model transfers to lung adenocarcinoma without retraining — strongly along the PI3K/AKT/mTOR axis (PIK3CA ρ=0.688, MTOR ρ=0.614, AKT1 ρ=0.583, EGFR ρ=0.561) but only modestly when pooled across all 16 LUAD-relevant targets (ρ=0.207, n=52,373). An integrated docking, ADMET, network-pharmacology, and leadoptimization pipeline screens 23,308 repurposing candidates, prioritizing 46 Tier-1 candidates, including 13 triple-validated elite compounds, with transparently reported safety pass rates (14.6%) traced to an EGFR/aniline training-corpus skew. The pipeline runs end-to-end on consumer-grade hardware, with code and protocols enabling transfer to other cancers.
Authors
- Saurabh Bundela (ORCID: https://orcid.org/0000-0002-7479-8591)
Publication Details
- Journal
- ChemRxiv
- Published
- 2026-11-20
- DOI
- https://doi.org/10.26434/chemrxiv.15012518/v1
- Primary Topic
- Computational Drug Discovery Methods
- Type
- preprint